However, participants reached a consensus of agreement on prescribing SGLT2 inhibitors to people with type 2 diabetes (regardless of ulceration status) with concurrent heart failure and/or chronic kidney disease, regardless of glycaemic control status. Here, SLC5A2 is linked to type 2 diabetes mellitus.